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Letters to the Editor
Eculizumab  for the treatment  of an atypical  hemolytic
uremic syndrome  with  mutations  in complement  factor  I
and C3
Eculizumab  para  el  tratamiento  de  un  síndrome  urémico  hemolítico
atípico  con  mutaciones  en  los  factores  I  y  C3  del  sistema  del
complemento
Atypical hemolytic-uremic syndrome (aHUS) is a rare,
life-threatening complement-mediated thrombotic
microangiopathy.1 Approximately half of cases have muta-
tions in complement proteins but only 12% have 2 or more
mutations.2 Eculizumab is nowadays considered ﬁrst-line
therapy for aHUS.3
A 33-year-old female with unremarkable past medical his-
tory presented with a 3-day history of decreased urine output.
Physical examination showed hypertension (160/90 mmHg)
and lower limbs edema. Investigations revealed an acute
thrombotic microangiopathy (ATM), hematuria and nephrotic
proteinuria (Table 1). Daily plasmapheresis (PMP) was started
immediately.
Investigations for secondary causes of ATM revealed a low
ADAMTS 13 activity, decreased complement C4, C3, C1q and
C2 levels and positive serum cryoglobulins (Table 1). Consid-
ering the hypothesis of an autoimmune disorder, we started 3
daily pulses of 1000 mg  methylprednisolone followed by oral
prednisolone.
PMP  was stopped on the eighteenth day of admission (D18)
due to normal platelet count during 3 consecutive days (Fig. 1).
On the D19 a renal biopsy was made. It showed a “thrombotic
microangiopathy with acute tubular necrosis” and “deposition
of IgM, C3 and C1q in the capillary wall”. Due to increased
hemolytic activity, PMP  was resumed on the D21. On the D27,
rituximab was started to enhance immunosuppression. PMP
was stopped on the D35 based on the absence of schistocy-
tosis, hemoglobin stability and lactate dehydrogenase (LDH)
normalization.
On the D50, LDH was high but hemoglobin and platelet
count were stable. A state of compensated hemolysis was
assumed and the patient was discharged home.Ten days later she was readmitted due to increased
hemolytic activity (Fig. 1). PMP  was resumed and 1000 mg
cyclophosphamide was given. At that time ADAMTS13 andcomplement C4 levels were normal but complement C3 levels
remained low.
A genetic screening for mutations in complement regula-
tory proteins was made. Two mutations were found in factor
I (C. 452 A>G, pASN 151 Ser) and C3 (C193 A > C, pLys 65 Gin)
proteins. The process of eculizumab acquisition was lengthy,
wherefore this therapy was started only on the 98th day
after readmission. At that moment we were performing one
PMP session/week, LDH remained high (859 U/L) and moderate
renal dysfunction (creatinine 2.08 mg/dL and urea 60 mg/dL)
and nephrotic proteinuria persisted (5.2 g/24 h). Eculizumab
was administered at a dose of 900 mg per week for 4 weeks
followed by subsequent doses of 1200 mg  every 2 weeks since
the 5th week. Complete hematologic remission was attained 2
days after eculizumab initiation. The patient was discharged
home on the 105th day after readmission. Four weeks later,
proteinuria was only 0.6 g/24 h.
Currently, 10 months after ﬁrst infusion, the patient
remains under biweekly administration of eculizumab. Hema-
tologic remission persists and there is a signiﬁcant recover of
renal function (urea 43 mg/dL, creatinine 1.27 mg/dL).
Complement factor I (CFI) and C3 mutations account
for 10% and 4% of the overall aHUS-associated mutations,
respectively.3 C3 mutations are among the ones with the poor-
est prognosis: 75% risk of death or end stage renal failure
(ESRF) at 3–5 years follow up and 50% risk of recurrence.3
CFI mutations have a 50–60% risk of death and ESRF at 3–5
years follow up and 10–30% risk of recurrence.3
Both mutations present in our patient were previously
reported.4,5 The p.Asn151Ser mutation causes a quantitative
deﬁciency of factor I4 and the p.Lys65Gin mutation weakens
the afﬁnity of C3b to complement factor H.5Despite the growing importance of eculizumab,6,7 PMP
remains the mainstay of treatment while waiting for the
immunoglobulin.3 Nonetheless, its beneﬁt depends on the
n e f r o l o g i a 2 0 1 6;3 6(1):72–87 73
Plasmapheresis
Corticosteroids
Rituximab Cyclophosphamide
Eculizumab
Second hospitalizationFirst hospitalization
Pl
as
m
a 
cr
ea
tin
in
e 
(m
g/d
L)
H
em
og
lo
bi
n 
(gr
/d
L)
La
ct
at
e 
de
hy
dr
og
en
as
e
(U
/L)
Pl
at
el
et
 c
ou
nt
(x1
03
/m
m
3)
4
3.5
3
2
1
0
14
12
10
8
6
4
2
0
 400
350
300
250
200
150
100
50
0
3500
3000
2500
2000
1500
1000
500
0
0 10 20 30 40 50 60 70 80 90 100
Days following first admission
 110 120 130 140 150 160 170 340
 450
2.5
1.5
0.5
Fig. 1 – Clinical course: laboratory data and treatment. Corticosteroid therapy was started with intravenous administration
of methylprednisolone (1000 mg/day for 3 days) followed by oral prednisolone and an initial dosage of 60 mg/day. This
dosage was maintained until the 53rd day after admission, with posterior tapering. Rituximab (arrows) was administered at
a dose of 600 mg  (375 mg/m2) on the 27th, 34th, 41st and 48th days after admission. Cyclophosphamide (arrowhead) was
administered in a single dose of 1000 mg  on the 61st day after admission (2nd day after readmission). Eculizumab was
administered at a dose of 900 mg  for a week for 4 weeks, started on the 158th day after admission, followed by a dosage of
1200 mg  1 week later an then a maintenance dose of 1200 mg  every 2 weeks. This dosage is still being continued. We
performed a total of 79 plasma exchange sessions. The last three laboratorial test results were  done on the 270th, 340th and
466th days following ﬁrst admission.
u
C
pnderlying genetic defect – only 25% and 57% of those with
FI and C3 mutations, respectively, achieve remission.8 In our
atient, PMP  was critical to prevent further progression ofrenal failure and the development of other systemic involve-
ment. However, as described by Loirat,2 it was unable to
achieve complete and sustained remission.
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Table 1 – Laboratorial results on admission and
additional studies to establish the cause of the
thrombotic microangiopathy.
On admission
Variable Result Normal
range
Hemoglobin (g/dL) 11.1 12–16
White-cell count (×103/mm3) 7.6 4–10
Platelet count (×103/mm3) 36  150–400
Peripheral blood smeara 10 schistocytes <2 schistocytes
Haptoglobin (g/L) <0.08 0.3–2
Direct coombs tests Negative Negative
Urea (mg/dL) 114 15–38
Creatinine (mg/dL) 2.9 0.52–1.04
Sodium (mmol/L) 135 137–145
Potassium (mmol/L) 3.6 3.5–5.1
Lactate dehydrogenase (U/L) 2827 313–618
c-Reactive protein (mg/dL) 0.6 <1.0
URINALYSIS
Protein (mg/dL) 1000
Leukocytes (/HPF) 3 <5/c
Red blood cells (/HPF) 28 <2/c
Urinary protein to creatinine
ratio (mg/mg)
14  <0.15
Additional studies
Variable Result Normal
range
C3 (g/L) 0.46 0.9–1.8
C4 (g/L) 0.02 0.1–0.4
CH50 (U/mL) 13 23–46
C1q (mg/L) 39 118–244
C1q Inhibitor (mg/L) 197 180/320
C2 (mg/L) 7.2 14–25
ADAMTS13 activity (%) 7% 40–130
Anti-ADAMTS13 antibody (U/mL) Negative <15
Serum cryoglobulins Positive
Auto-immune antibodiesb,
Pregnancy test, SPE, Tumoral
markersc, HIV, HBV, HCV
Negative/Normal
Blood, urine and stool cultures Negative
Upper endoscopy, colonoscopy,
cervical, thoracic and
abdominopelvic CT
Irrelevant changes
a Peripheral blood smear was done to evaluate presence of ery-
throcyte fragmentation and is reported as schistocytes count in
a microscopic ﬁeld at 100×  magniﬁcation.
b Antinuclear antibodies, extractable nuclear antigens, anti-
neutrophil cytoplasmic antibodies, glomerular basement
membrane, rheumatoid factor, cyclic citrullinated peptide,
anticardiolipin/anti-2-glycoprotein, Lupus anticoagulant.
c Carcinoembryonic antigen, carbohydrate antigen 19-9, -
fetoprotein, cancer antigen 125, neuron-speciﬁc enolase, NSE.
Abbreviations: ADAMTS13; a disintegrin and metalloproteinase
with a thrombospondin type 1 motif; member 13. CT; com-
rputerized tomography. HBV; hepatitis B virus. HCV; hepatitis C
virus. HIV; human immunodeﬁciency virus. SPE; serum protein
electrophoresis.
In our case, the confounding presence of low ADAMTS13,
C4, C2 and C1q levels, the presence of cryoglobulins and the
existence of immune deposits in the glomerular capillary wall
led to the misdiagnosis of a thrombotic thrombocytopenic
purpura secondary to an autoimmune disease. It explains
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the preference for glucocorticoids, rituximab and cyclophos-
phamide in relation to eculizumab.9
Eculizumab is nowadays considered ﬁrst-line therapy for
aHUS.3 It is a humanized monoclonal immunoglobulin IgG
that targets C5 and blocks the uncontrolled generation of
the cytotoxic membrane attack complex.10 When we  started
Eculizumab, our patient was still PMP  dependent despite
the 79 PMP sessions. Contrariwise, complete hematologic
remission was attained two days after ﬁrst infusion and a
remarkable recover of renal function and reduction of pro-
teinuria was evident. These ﬁndings reinforce the beneﬁts of
eculizumab in aHUS, even in cases of severe renal involve-
ment.
In conclusion, our case highlights the diagnostic challenge
of aHUS and emphasizes the notion that isolated PMP is no
longer the best therapeutic option in aHUS, in which cases a
prompt switch to eculizumab is mandatory.
The authors declare that they have no conﬂicts of interest
related to the contents of this article.
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ethylmalonic  acidemia  with  emergency  hypertension
cidemia  metilmalónica  con  hipertensión  de  emergencia
ear Editor,
ethylmalonic acidemia (MMA)  is a heterogeneous disor-
er of propionate metabolism. MMA  is caused by deﬁciency
f the mitochondrial enzyme, methylmalonyl-CoA mutase-
poenzyme activity (MUT) or defective in adenosylcobalamin
coenzyme) synthesis.1 The most patients with cblA and half
atients with cblB forms of MMA  are responsive to vita-
in  B12.2,3 Clinical manifestation of MMA  may be acute
r chronic. The acute form of the disease occurs during
nfancy and even as early as the second day of life with
oor feeding, vomiting, dehydration, weight loss, tempera-
ure instability, lethargy, hypotonia, seizure and progressing
o coma. Laboratory ﬁndings include: metabolic acidosis,
etosis, hypoglycemia, hyperlactatemia, hyperammonemia,
ancytopenia.4
Deﬁnitive diagnosis of isolated MMA  is based on analy-
is of organic acids in plasma and/or urine; however genetic
esting diagnosis in some condition is accessible to conﬁrm
he diagnosis of isolated MMA.  Below, we  describe the pre-
entation and management of two cases of MMA with severe
ypertention.
The ﬁrst case was a 46-day-old girl, admitted to the emer-
ency department because of generalized edema and severe
ypertension. She was born from consanguineous parents at
erm with a birth weight 2.600 kg. She had frequent vomi-
ing in 9th day of life. Edema of hands and feet appeared in
9th day of life. On admission, she had SBP 130 mmHg  (above
9th), DBP 75 mmHg  (above 99th), periorbital and legs pitting
dema and respiratory distress. Laboratory ﬁndings included:
icroscopic hematuria, massive proteinuria, hypoalbomine-
ia, pancytopenia and high anion gap metabolic acidosis.
The patient was managed by nephrologists with diagnosis
f congenital nephrotic syndrome. Angiography of abdominal
orta and renal artery were normal. She had brain atro-
were seen larger than normal. Bone marrow aspiration (BMA)
was performed because of pancytopenia which was nor-
mal. Patient’s hypertension did not respond to Losartan,
Hydralazine, Captopril and Amlodipine. Metabolic consulting
and then metabolic tests due to refractory metabolic acidosis
was done. The patient with suspected organic aciduria was
treated with hydroxycobalamin 1 mg  daily, biotin 10 mg  daily
and l-carnitine 50 mg/kg/day. She had high level of glycine
in blood amino acid chromatography but ammonia, lactate,
serum B12 and hemocystein were normal. Methylmalonic
aciduria conﬁrmed with high level of urine methlmalonic acid
and increased serum level of propionyl carnitine. We  have
increased the dose of B12 up to 2 mg  IM daily but unfortunately,
the patient died.
The second case was a 45-day-old boy admitted from
the emergency ward with complaints of anemia, respiratory
distress and severe hypertension. He was born from non-
consanguineous parents at term with a birth weight 2.800 kg.
The ﬁrst baby of the family had died at the age of 5-months due
to propionic aciduria. On examination he had respiratory dis-
tress (RR = 67), SBP 134 mmHg  (above 99th) and DBP 78 mmHg
(above 99th) and mild pitting edema in legs. Laboratory results
included: high anion gap metabolic acidosis, pancytopenia,
hypoalbominemia, proteinuria, and microscopic hematuria.
Lactate, ammonia, serum B12, serum hemocystein and other
electrolytes were normal but serum glycine was increased.
Renal artery disorder has been excluded by Doppler sonogra-
phy. Abdominal sonography was normal but both kidneys had
upper normal size and increased cortical echogenicity. BMA
was performed because of pancytopenia which was normal.
According to the familial history and our previous case, after
sending samples for urine organic acid, acylcarnitine proﬁle
and chromatography of serum amino acid, B12 2 mg  IM daily,
carnitine 50 mg/kg/day, biotin 10 mg  daily and low protein diet
was started for the patient. His blood pressure was refractoryhy and supra and infra tentorial ventricolomegaly in brain
T scan and left ventricular hypertrophy in echocardiogra-
hy. Abdominal sonography was normal but both kidneysto all of anti-hypertensive drugs such as Hydralazine, Capto-
pril, Labetalol. Methylmalonic aciduria conﬁrmed by increased
of urine methylmalonic acid and serum propionyl carnitine.
